TY - JOUR
T1 - Evaluation of T- and NK-Cell-Targeted therapies
T2 - Is there a role for rituximab prophylaxis?
AU - Ambinder, Richard F.
PY - 2009/4/1
Y1 - 2009/4/1
N2 - Splizimomab, an antibody that targets CD2, was studied in the treatment of Tand natural killer cell lymphoma and was found to be associated with Epstein-Barr virus lymphoproliferative disease. B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion.
AB - Splizimomab, an antibody that targets CD2, was studied in the treatment of Tand natural killer cell lymphoma and was found to be associated with Epstein-Barr virus lymphoproliferative disease. B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion.
UR - http://www.scopus.com/inward/record.url?scp=65249085023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65249085023&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-08-2905
DO - 10.1158/1078-0432.CCR-08-2905
M3 - Short survey
C2 - 19293254
AN - SCOPUS:65249085023
SN - 1078-0432
VL - 15
SP - 2205
EP - 2206
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 7
ER -